NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: VolitionRx's Nu.Q Vet Feline Test for Detecting Lymphoma in Cats
TL;DR
VolitionRx's Nu.Q Vet Feline assay offers veterinarians a competitive edge with a simple, affordable blood test that detects over 80% of feline lymphomas without false positives.
VolitionRx's blood-based Nu.Q Vet Feline assay works by detecting lymphoma in cats with 100% specificity and over 80% sensitivity, using epigenetic markers for early diagnosis.
VolitionRx's feline cancer test makes the world better by enabling earlier, less invasive detection of lymphoma in cats, potentially improving survival rates and quality of life.
VolitionRx's breakthrough test detects feline lymphoma through a simple blood draw, offering the first affordable liquid biopsy for cats' most common cancer.
Found this article helpful?
Share it with your network and spread the knowledge!
VolitionRx announced clinical study results demonstrating the high accuracy of its Nu.Q Vet Feline blood test in detecting lymphoma, the most common cancer in cats.
VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company focused on developing blood tests for disease detection and monitoring in both humans and animals.
The test showed 100% specificity (no false positives) and detected more than 80% of feline lymphomas in the clinical study.
Feline cancer has historically been difficult to diagnose early, often requiring invasive biopsies or costly imaging after symptoms have progressed, and veterinarians have sought a feline screening solution for years.
It is a blood-based liquid biopsy test that detects lymphoma through epigenetic analysis, making it simpler and less invasive than traditional diagnostic methods.
Unlike invasive biopsies or costly imaging that typically occur after symptoms appear, this is a simple, affordable blood test that could enable earlier detection.
VolitionRx plans to complete product development and make the Nu.Q Vet Feline Test available through existing distribution networks, though no specific timeline is provided in the content.
The company plans to make it available through existing distribution networks, including reference laboratories and point-of-care platforms.
The company has previously rolled out a canine cancer test internationally and is developing blood tests for various diseases including some cancers and conditions associated with NETosis, such as sepsis.
For further information, visit the company's website at https://volition.com/ or view the full press release at https://ibn.fm/SI9RB.
Curated from InvestorBrandNetwork (IBN)
